Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimen

Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients

Summary:

Graft rejection in patients with severe aplastic anemia (SAA) following allogeneic hematopoietic stem cell transplantation (HSCT) is strongly associated with a large number of prior transfusions and with prolonged disease duration before transplant. We retrospectively analyzed the outcomes and the factor affecting these multitransfused SAA patients, who had received triple agent immunosuppression and high doses of stem cells to overcome rejection. In total, 113 patients with SAA who had a median 16 months (range 1–216) of disease duration were transplanted using HLA-matched sibling donors after conditioning with cyclophosphamide (CY), procarbazine (PCB), and ATG. Graft failure occurred in 16 of the eligible 113 patients, and with a median follow-up of 30 months (range, 1–80), probability of overall rejection was 15%. Specifically, the multitransfused patients who received high doses of stem cells with T-cell depletion showed the lowest rejection rate, 5.6%, compared with 30.3% in multitransfused patients with bone marrow stem cells alone (P=0.0310). Disease duration (P=0.0338) and the number of infused CD34+cells (P=0.0101) were associated with a high risk of graft rejection on multivariate analysis. ABO mismatch and the number of CD34+ cells were significant factors in the incidence of acute graft-versus-host-disease (GVHD). The incidence of chronic GVHD among patients with sustained engraftment was 13/109 (11.9%). With the same follow-up period, probability of disease-free survival for the entire group of patients at 6 years was 89% and the only factor associated with long-term survival was rejection (P=0.0241). These results suggest that allogeneic HSCT conditioned with triple agent immunosuppression, and specifically with high-dose stem cell return is probably an effective treatment for successful engraftment in SAA patients with a high risk of rejection.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Camitta BM, Thomas ED, Nathan DG et al. A Prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979; 53: 504–514.

    CAS  Google Scholar 

  2. Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anemia by antithymocyte globulin with and with- out allogeneic bone-marrow infusions. Lancet 1977; iv: 1145–1148.

    Article  Google Scholar 

  3. Bacigalupo A, Broccia G, Corda G et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 1995; 85: 1348–1353.

    CAS  PubMed  Google Scholar 

  4. Thomas ED, Storb R, Giblett ER et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol 1976; 4: 97–102.

    CAS  PubMed  Google Scholar 

  5. Wright SE, Thomas ED, Buckner CD et al. Experience with second marrow transplants. Exp Hematol 1976; 4: 221–226.

    CAS  PubMed  Google Scholar 

  6. Meuwissen HJ, Moore EC, Strauss HS et al. Successful retransplantation of bone marrow following failure of initial engraftment in a patient with aplastic anemia. J Pediatr 1976; 89: 588–592.

    Article  CAS  Google Scholar 

  7. Storb R, Thomas ED, Weiden PL et al. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood 1976; 48: 817–841.

    CAS  PubMed  Google Scholar 

  8. Gluckman E, Horowitz MM, Champlin RE et al. Bone Marrow Transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269–275.

    CAS  Google Scholar 

  9. Arranz R, Otero MJ, Ramos R et al. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. Bone Marrow Transplant 1994; 13: 383–387.

    CAS  PubMed  Google Scholar 

  10. Deeg HJ, Leisenring W, Storb R et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637–3645.

    CAS  PubMed  Google Scholar 

  11. Bacigalupo A, Oneto R, Bruno B et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for blood and marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol 2000; 103: 19–25.

    Article  CAS  Google Scholar 

  12. Ball SE. The modern management of severe aplastic anaemia. Br J Haematol 2000; 110: 41–53.

    Article  CAS  Google Scholar 

  13. Passweg JR, Socie G, Hinterberger W et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood 1997; 90: 858–864.

    CAS  Google Scholar 

  14. Storb R, Blume KG, O'Donnell MR et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39–44.

    Article  CAS  Google Scholar 

  15. Weiden PL, Storb R, Thomas ED et al. Preceding transfusions and marrow graft rejection in dogs and man. Transplant Proc 1976; 8: 551–554.

    CAS  PubMed  Google Scholar 

  16. Bacigalupo A. Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression therapy. Working Party on Severe Aplastic Anaemia of the European blood and marrow transplantation Group. Eur J Haematol 1996; 60 (Suppl.): 16–19.

    CAS  Google Scholar 

  17. May WS, Sensenbrenner LL, Burns WH et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant 1993; 11: 459–464.

    CAS  Google Scholar 

  18. Young NS, Maciejewsi J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365–1372.

    Article  CAS  Google Scholar 

  19. Young NS. Autoimmunity and its treatment in aplastic anemia. Ann Intern Med 1997; 126: 166–168.

    Article  CAS  Google Scholar 

  20. Herrera-Garza J, Jaime-Perez J, Montermayor J et al. High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen. Bone Marrow Transplant 1999; 24: 845–848.

    Article  CAS  Google Scholar 

  21. Naparstek E, Delukina M, Or R et al. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Exp Hematol 1999; 27: 1210–1218.

    Article  CAS  Google Scholar 

  22. Dufour C, Dallorso S, Casarino L et al. Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant. 1999; 23: 743–745.

    Article  CAS  Google Scholar 

  23. Thomas ED, Storb R, Giblett ER et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol 1976; 4: 97–102.

    CAS  PubMed  Google Scholar 

  24. Parkman R, Rappeport J, Camitta B et al. Successful use of multiagent immunosuppression in the bone marrow transplantation of sensitized patients. Blood 1978; 52: 1163–1169 .

    CAS  PubMed  Google Scholar 

  25. Gluckman E, Horowitz MM, Champlin RE et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269–275.

    CAS  Google Scholar 

  26. Min CK, Kim DW, Lee JW et al. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Acta Haematol 2000; 104: 185–192.

    Article  CAS  Google Scholar 

  27. Min CK, Kim DW, Lee JW et al. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Haematologica 2001; 86: 303–310.

    CAS  PubMed  Google Scholar 

  28. Min CK, Kim DW, Lee JW et al. Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia. Am J Hematol 2002; 69: 15–22.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, H., Park, C., Park, Y. et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant 31, 79–86 (2003). https://doi.org/10.1038/sj.bmt.1703786

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703786

Keywords

This article is cited by

Search

Quick links